These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 7064434)

  • 1. Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services?
    Vox Sang; 1982 Feb; 42(2):97-109. PubMed ID: 7064434
    [No Abstract]   [Full Text] [Related]  

  • 2. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
    Tremper KK; Anderson ST
    Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyhemoglobin and fluorocarbon as blood substitutes.
    Moss GS; Gould SA; Sehgal LR; Rosen AL; Sehgal HL
    Biomater Artif Cells Artif Organs; 1987; 15(2):333-6. PubMed ID: 3447649
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical experience with Fluosol-DA (20%) in the United States.
    Tremper KK; Levine EM; Waxman K
    Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514
    [No Abstract]   [Full Text] [Related]  

  • 5. Red cell substitutes: present status.
    Sehgal LR; Sehgal HL; Gould SA; Rosen AL; DeWoskin R; Moss GS
    Indian J Pediatr; 1987; 54(3):403-8. PubMed ID: 3301660
    [No Abstract]   [Full Text] [Related]  

  • 6. Medical oxygen transport using perfluorochemicals.
    Kaufman RJ
    Biotechnology; 1991; 19():127-62. PubMed ID: 1786469
    [No Abstract]   [Full Text] [Related]  

  • 7. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
    [No Abstract]   [Full Text] [Related]  

  • 8. Blood substitutes: oxygen-carrying acellular fluids.
    Wohl JS; Cotter SM
    Vet Clin North Am Small Anim Pract; 1995 Nov; 25(6):1417-40. PubMed ID: 8619274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and clinical application of perfluorochemical artificial blood.
    Ohyanagi H; Saitoh Y
    Int J Artif Organs; 1986 Sep; 9(5):363-8. PubMed ID: 3781670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protective effect of mannitol and perfluorochemicals on hemorrhagic infarction: an experimental study.
    Kagawa S; Koshu K; Yoshimoto T; Suzuki J
    Surg Neurol; 1982 Jan; 17(1):66-70. PubMed ID: 6803373
    [No Abstract]   [Full Text] [Related]  

  • 11. [The place for using erythrocyte substitutes in hemodilution: fluosol-DA and polymerized pyridoxylated hemoglobin].
    Vigneron C; Labrude P; Dellacherie E
    Ann Fr Anesth Reanim; 1986; 5(3):260-8. PubMed ID: 3535579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hemodilution with dextran, stroma-free hemoglobin solution and fluosol-DA on experimental myocardial ischemia in the dog.
    Biro GP
    Bibl Haematol; 1981; (47):54-69. PubMed ID: 6175307
    [No Abstract]   [Full Text] [Related]  

  • 13. (Pyridoxylated hemoglobin)-(polyoxyethylene) conjugate solution as blood substitute for normothermic whole body rinse-out.
    Agishi T; Funakoshi Y; Honda H; Yamagata K; Kobayashi M; Takahashi M
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):261-70. PubMed ID: 3179468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cell substitutes.
    Rentko VT
    Probl Vet Med; 1992 Dec; 4(4):647-51. PubMed ID: 1472775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
    Stefaniszyn HJ; Wynands JE; Salerno TA
    J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of various colloidal solutions during major abdominal surgery.
    Nishimura N; Hiranuma N; Sugi T
    Crit Care Med; 1983 Dec; 11(12):940-2. PubMed ID: 6196154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood substitutes as therapy in massive surgery and trauma.
    Tye RW
    Prog Clin Biol Res; 1982; 108():79-89. PubMed ID: 6817339
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK; Lapin R; Levine E; Friedman A; Shoemaker WC
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perfluorocarbons: future clinical possibilities.
    Clark MC; Weiman DS; Pate JW; Gir S
    J Invest Surg; 1997; 10(6):357-65. PubMed ID: 9654392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can "artificial blood' live up to public billing?
    Cowart VS
    JAMA; 1982 Feb; 247(8):1104-5. PubMed ID: 7057595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.